231 related articles for article (PubMed ID: 25201433)
1. Measuring performance in off-patent drug markets: a methodological framework and empirical evidence from twelve EU Member States.
Kanavos P
Health Policy; 2014 Nov; 118(2):229-41. PubMed ID: 25201433
[TBL] [Abstract][Full Text] [Related]
2. The Evolution of Supply and Demand in Markets for Generic Drugs.
Frank RG; McGuire TG; Nason I
Milbank Q; 2021 Sep; 99(3):828-852. PubMed ID: 34075623
[TBL] [Abstract][Full Text] [Related]
3. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
4. Impact of European pharmaceutical price regulation on generic price competition: a review.
Puig-Junoy J
Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
[TBL] [Abstract][Full Text] [Related]
5. Price regulation and relative delays in generic drug adoption.
Costa-Font J; McGuire A; Varol N
J Health Econ; 2014 Dec; 38():1-9. PubMed ID: 25200940
[TBL] [Abstract][Full Text] [Related]
6. Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.
Wouters OJ; Kanavos PG; McKEE M
Milbank Q; 2017 Sep; 95(3):554-601. PubMed ID: 28895227
[TBL] [Abstract][Full Text] [Related]
7. The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.
Kwon HY; Kim H; Godman B; Reich MR
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):1007-14. PubMed ID: 26394767
[TBL] [Abstract][Full Text] [Related]
8. A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China.
Zeng W
BMC Health Serv Res; 2013 Oct; 13():390. PubMed ID: 24093493
[TBL] [Abstract][Full Text] [Related]
9. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
Roughead EE; Kim DS; Ong B; Kemp-Casey A
WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
[TBL] [Abstract][Full Text] [Related]
10. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure.
Magazzini L; Pammolli F; Riccaboni M
Eur J Health Econ; 2004 Jun; 5(2):175-82. PubMed ID: 15452754
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical policy regarding generic drugs in Belgium.
Simoens S; De Bruyn K; Bogaert M; Laekeman G
Pharmacoeconomics; 2005; 23(8):755-66. PubMed ID: 16097838
[TBL] [Abstract][Full Text] [Related]
12. The diffusion of generics after patent expiry in Germany.
Fischer KE; Stargardt T
Eur J Health Econ; 2016 Nov; 17(8):1027-1040. PubMed ID: 26573841
[TBL] [Abstract][Full Text] [Related]
13. Do generics offer significant savings to the UK National Health Service?
Kanavos P
Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
[TBL] [Abstract][Full Text] [Related]
14. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
[TBL] [Abstract][Full Text] [Related]
15. Does the market share of generic medicines influence the price level?: a European analysis.
Dylst P; Simoens S
Pharmacoeconomics; 2011 Oct; 29(10):875-82. PubMed ID: 21797288
[TBL] [Abstract][Full Text] [Related]
16. Need for multicriteria evaluation of generic drug policies.
Kaló Z; Holtorf AP; Alfonso-Cristancho R; Shen J; Ágh T; Inotai A; Brixner D
Value Health; 2015 Mar; 18(2):346-51. PubMed ID: 25773570
[TBL] [Abstract][Full Text] [Related]
17. The impact of price-cap regulations on market entry by generic pharmaceutical firms.
Zhang W; Sun H; Guh D; Anis AH
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):231-238. PubMed ID: 27936981
[TBL] [Abstract][Full Text] [Related]
18. Encouraging the use of generic medicines: implications for transition economies.
King DR; Kanavos P
Croat Med J; 2002 Aug; 43(4):462-9. PubMed ID: 12187525
[TBL] [Abstract][Full Text] [Related]
19. High prices for generics in Australia - more competition might help.
Bulfone L
Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic substitution post-patent expiry: the cases of ACE inhibitors and proton pump inhibitors.
Vandoros S
Health Econ; 2014 May; 23(5):621-30. PubMed ID: 23696193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
